Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection

Clinical Trial ID NCT04513158

PubWeight™ 0.00^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04513158

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.	Lancet Oncol	2020	18.57
2	Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.	Lancet	2020	18.32
3	Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.	Lancet	2020	10.16
4	Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.	Lancet Respir Med	2020	10.13
5	Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.	JAMA	2020	6.59
6	Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea.	N Engl J Med	2016	6.22
7	The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.	J Infect Dis	2014	1.88
8	Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.	Clin Infect Dis	2011	1.68
9	Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS).	Thorax	2003	1.40
10	Use of convalescent plasma therapy in SARS patients in Hong Kong.	Eur J Clin Microbiol Infect Dis	2005	1.23
11	Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol.	Springerplus	2015	0.96